The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK Biobank
Open Access
- 9 August 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 57 (12) , 2172-2182
Abstract
To compare the prevalence and incidence of chronic co-morbidities in people with inflammatory rheumatic and musculoskeletal diseases (iRMDs), and to determine whether the prevalent co-morbidities are associated with physical activity levels in people with iRMDs and in those without iRMDs. Participants were recruited to the UK Biobank; a population-based cohort. Data were collected about demographics, physical activity, iRMDs (RA, PsA, AS, SLE) and other chronic conditions, including angina, myocardial infarction, stroke, hypertension, pulmonary disease, diabetes and depression. The standardized prevalence of co-morbidities in people with iRMDs was calculated. Cox regression was used to determine the relationship between the presence of an iRMD and an incident co-morbidity. The relationship between the presence (versus absence) of a (co-)morbidity and physical activity level (low, moderate, high) in people with iRMDs and in those without was assessed using multinomial logistic regression. A total of 488 991 participants were included. The estimated prevalence of each co-morbidity was increased in participants with an iRMD, compared with in those without, particularly for stroke in participants with SLE (standardized morbidity ratio (95% CI), 4.9 (3.6, 6.6). Compared with people with no iRMD and no morbidity, the odds ratios (95% CI) for moderate physical activity were decreased for: no iRMD and morbidity, 0.87 (0.85, 0.89); iRMD and no co-morbidity, 0.71 (0.64, 0.80); and iRMD and co-morbidity, 0.58 (0.54, 0.63). Having a (co-)morbidity is associated with reduced physical activity in the general population, and to a greater extent in participants with an iRMD. Optimal management of both iRMDs and co-morbidities may help to reduce their impact on physical activity.Keywords
Funding Information
- Arthritis Research UK (20385)
- NIHR Manchester Musculoskeletal Biomedical Research Unit
This publication has 38 references indexed in Scilit:
- Comparison of measures of comorbidity for predicting disability 12-months post-injuryBMC Health Services Research, 2013
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studiesAnnals of the Rheumatic Diseases, 2012
- Prevalence of spondyloarthritis and its subtypes in southern SwedenAnnals of the Rheumatic Diseases, 2011
- Epidemiology of CVD in rheumatic disease, with a focus on RA and SLENature Reviews Rheumatology, 2011
- Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohortsClinical Rheumatology, 2011
- Enhancing the Feasibility of Large Cohort StudiesJAMA, 2010
- Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based studyAnnals of the Rheumatic Diseases, 2010
- Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseasesArthritis Research & Therapy, 2009
- UK Biobank: bank on itThe Lancet, 2007